Go Backs
HomeCategoriesStatesCheck Your Home
Go Backs

Track product recalls and safety alerts from CPSC, FDA, NHTSA, and USDA. Stay informed and keep your family safe.

Browse

  • Categories
  • States
  • Check Your Home
  • Risk Levels

Agencies

  • CPSC
  • FDA Food
  • FDA Drug
  • FDA Device
  • FDA Veterinary
  • NHTSA
  • USDA

Company

  • About
  • FAQ
  • Contact
  • Terms of Service
  • Privacy Policy

Recall data is sourced from official U.S. government agencies (CPSC, FDA, NHTSA, USDA) and processed using AI to improve readability. This site is not affiliated with or endorsed by any government agency. Always refer to the original agency notice for authoritative information.

© 2026 Go Backs. All rights reserved.

High RiskFDA Drug
Medications & Supplements/Prescription Drugs

B AND A TRADING CORPORATION: Kushim Tablets Recalled for Unapproved and Potentially Toxic Ingredients

Agency Publication Date: February 12, 2020
Share:
Sign in to monitor this recall

Summary

B AND A TRADING CORPORATION is recalling 40 packages of Kushim Tablets (also known as Gushim) in 45-count containers. These products were marketed without an approved New Drug Application or Abbreviated New Drug Application, meaning they have not been evaluated by the FDA for safety or effectiveness. Laboratory analysis discovered the tablets contain cinobufagin, bufalin, and bufotenine, which are substances that can have serious effects on the heart and nervous system. These tablets featured labels in a foreign language and were distributed only in New York and New Jersey.

Risk

The product contains cinobufagin, bufalin, and bufotenine, which are potent compounds typically derived from toad venom that can cause irregular heartbeats, dangerously high blood pressure, and respiratory distress. These substances pose a significant health risk because they can lead to cardiac arrest or death if ingested.

What You Should Do

  1. Check your medicine cabinet for 45-count packages of Kushim Tablets (Gushim) labeled in a foreign language.
  2. Verify if your package matches Lot #: H003, which is the specific batch affected by this recall.
  3. Stop using this product immediately and do not consume any remaining tablets.
  4. Contact your healthcare provider or pharmacist for guidance regarding any health concerns or potential side effects experienced after using this product.
  5. Return any unused product to the place of purchase for a full refund and contact B AND A TRADING CORPORATION at their Carlstadt, NJ location for further instructions.
  6. For additional questions, contact the FDA Consumer Complaint hotline at 1-888-723-3332 (1-888-SAFEFDA) or visit www.fda.gov/safety/recalls.

Your Remedy Options

💰Full Refund

Manufacturer refund and healthcare consultation.

How to: Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund

Affected Products

Product: Kushim Tablets (Gushim) 45-count packages
Model:
D-0840-2020
Lot Numbers:
H003

Additional Information

Agency: Food and Drug Administration (FDA)
Event ID: 84827
Status: Resolved
Manufacturer: B AND A TRADING CORPORATION
Manufactured In: United States
Units Affected: 40 packages
Distributed To: New York, New Jersey

Were You Affected by This Recall?

If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.

Find an Attorney

This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.

AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.

Sources: FDA iRES · Raw API Response

openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.